Tech Company M&A Transactions
Signature Therapeutics Acquisition
Signature Therapeutics, operating out of Palo Alto, was acquired by Ensysce Biosciences. What Ensysce Biosciences paid for Signature Therapeutics was not disclosed.
Transaction Overview
Company Name
Acquired By
Announced On
1/20/2016
Transaction Type
M&A
Amount
Unknown
M&A Terms
Ensysce Biosciences and Signature Therapeutics are pleased to announce completion of a formal merger on Dec. 31, 2015, naming Dr. Lynn Kirkpatrick as CEO. The company will retain the name of Ensysce Biosciences and will be relocating to San Diego, California. Financial terms of the transaction were not disclosed.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1731 Embarcadero Road 220
Palo Alto, CA 94303
USA
Palo Alto, CA 94303
USA
Phone
Website
Email Address
Overview
Signature Therapeutics creates value through our ability to efficiently advance relatively low risk drug discovery and development programs, which address large markets with clearly defined unmet needs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Wesley Sterman
Chief Medical Officer
Bill Schmidt
VP - Operations
Judy Magruder
Browse more venture capital transactions:
Prev: 1/20/2016: Telensa venture capital transaction
Next: 1/20/2016: eRated venture capital transaction
Share this article
About Database of VC Transactions
We document every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs